Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Zuretinol acetate - Novelion Therapeutics

Next Previous
Drug Profile

Zuretinol acetate - Novelion Therapeutics

Alternative Names: 9-cis-Retinol; BBP-551; EB-109; EB-116; QLT-091001; Synthetic retinaldehyde; Synthetic retinoid

Latest Information Update: 28 Jun 2022

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator QLT; Retinagenix Therapeutics
  • Developer Novelion Therapeutics
  • Class Eye disorder therapies; Eye proteins; Retinaldehydes; Retinoids; Small molecules
  • Mechanism of Action Acyltransferase stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Retinitis pigmentosa; Leber congenital amaurosis
  • New Molecular Entity Yes
  • Available For Licensing Yes - Leber congenital amaurosis; Retinitis pigmentosa

Highest Development Phases

  • Phase III Leber congenital amaurosis; Retinitis pigmentosa
  • Phase II Nyctalopia

Most Recent Events

  • 28 Jun 2022 No recent reports of development identified for phase-I development in Leber-congenital-amaurosis in Canada (PO, Liquid)
  • 28 Jun 2022 No recent reports of development identified for phase-I development in Leber-congenital-amaurosis in Germany (PO, Liquid)
  • 28 Jun 2022 No recent reports of development identified for phase-I development in Leber-congenital-amaurosis in Netherlands (PO, Liquid)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top